Skip to main content
. 2020 Jul 16;6(1):e12050. doi: 10.1002/trc2.12050

FIGURE 2.

FIGURE 2

Mechanisms of action of agents in Phase 3 of the Alzheimer's disease drug development pipeline (ClinicalTrials.gov accessed February 27, 2020) (Figure by Mike de la Flor)